Wegovy Weight-Loss Pill Arrives in Israel, Offering Oral Alternative
Translated & summarized from Mako by baba
The oral version of the Wegovy weight-loss drug is now available in Israel by prescription, offering an alternative to injections. The daily pill contains semaglutide and does not require refrigeration, but may be less effective than the injectable form. It is intended for adults with a BMI of 30 or higher, or 27 with comorbidities, and requires specific daily intake instructions. Potential side effects include gastrointestinal issues and the risk of nutritional deficiencies.
The story in 6 lines · by baba
- The oral Wegovy weight-loss pill is now available in Israel by prescription.
- The daily pill offers an alternative to injections and does not require refrigeration.
- It contains semaglutide and mimics the GLP-1 hormone to reduce appetite.
- The pill may be slightly less effective than the injectable form.
- It is indicated for adults with a BMI of 30+ or 27+ with comorbidities.
- Potential side effects include gastrointestinal issues and nutritional deficiencies.
The oral version of the Wegovy weight-loss medication is set to become available this week at private pharmacies in Israel, requiring a doctor's prescription. This pill offers an alternative for individuals struggling with obesity who are hesitant about injections or find them inconvenient. It contains semaglutide, the same active ingredient as the injectable Wegovy, which mimics the GLP-1 hormone to increase feelings of fullness and reduce appetite.
Key advantages of the pill include the elimination of the need for injections and the convenience of not requiring refrigeration, making it easier for travelers. However, unlike the weekly injection, the pill must be taken daily under specific conditions to ensure proper absorption. Patients must take it on an empty stomach after at least an eight-hour fast, with a small amount of water, and wait at least 30 minutes before eating, drinking, or taking other oral medications.
While the pill offers greater convenience, it may be slightly less effective than the injectable form. A 64-week study, OASIS 4, involving 307 participants, showed an average weight loss of 16.6% when adherence was assumed, and about 14% when treatment interruptions were factored in. The choice between the pill and injection should consider the patient's medical condition, response to treatment, ability to adhere to the regimen, and personal preferences.
The treatment is intended for adults with a Body Mass Index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension or type 2 diabetes. Consultation with a doctor is crucial to assess overall health, pre-existing conditions, and current medications.
Potential side effects are primarily gastrointestinal, including nausea, abdominal pain, diarrhea, vomiting, and constipation. These can often be managed by gradually increasing the dosage, a strategy designed to help the body adapt to the medication. Significant or worsening side effects, such as severe abdominal pain that could indicate pancreatitis, or vomiting and diarrhea leading to dehydration, require immediate medical attention. Additionally, the reduced appetite and food intake could lead to nutritional deficiencies, necessitating careful monitoring.
